NVLX $.1325 Nuvilex's pancreatic cancer treatment
Post# of 1086
Posted On: 09/24/2013 3:36:08 PM
NVLX $.1325 Nuvilex's pancreatic cancer treatment helped patients to a far better outcome than that previously reported with standard single-drug gemcitabine and even that reported for the just approved ABRAXANE-gemcitabine combination.
http://www.nuvilex.com/
Nuvilex has recently acquired worldwide exclusive rights to the live cell-encapsulation technology described above from SG Austria Pte. Ltd. for the development of treatments for any and all types of cancer. The rights to use the cancer drug-activating cells (22P1G cells) that will be part of Nuvilex’s treatment for advanced pancreatic cancer were also acquired.
http://www.nuvilex.com/
Nuvilex has recently acquired worldwide exclusive rights to the live cell-encapsulation technology described above from SG Austria Pte. Ltd. for the development of treatments for any and all types of cancer. The rights to use the cancer drug-activating cells (22P1G cells) that will be part of Nuvilex’s treatment for advanced pancreatic cancer were also acquired.
(0)
(0)PharmaCyte Biotech Inc. (PMCB) Stock Research Links
Scroll down for more posts ▼